Novo Nordisk launches blockbuster weight-loss drug Wegovy in India

Novo Nordisk has officially launched its highly anticipated weight-loss drug, Wegovy, in the Indian market. This development marks a significant milestone in the pharmaceutical landscape, offering a new option for those struggling with obesity. Wegovy, known for its effectiveness in aiding weight loss, is expected to meet the growing demand for medical interventions in this field. The drug will be available in two dosage forms: 1.75 mg and 2.4 mg. The 2.4 mg dosage, in particular, is priced at ₹24,280, positioning it as a premium option for consumers. Wegovy's introduction comes at a time when India is witnessing a rise in obesity-related health issues, making it a timely addition to the healthcare arsenal. While Novo Nordisk has not disclosed the pricing for the 1.75 mg dosage, the launch is anticipated to generate significant interest among healthcare providers and patients alike. As Wegovy enters the Indian market, it is poised to play a pivotal role in the country's fight against obesity, offering new hope to many individuals seeking to achieve healthier lifestyles.

— Authored by Next24 Live